Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.

Drug metabolism and disposition: the biological fate of chemicals - 1 May 2009

Bains Onkar S, Karkling Morgan J, Grigliatti Thomas A, Reid Ronald E, Riggs K Wayne

Abstract excerpt

Carbonyl reductases (CBRs) are a group of metabolic enzymes belonging to the short-chain dehydrogenase family with NADPH-dependent oxidoreductase activity. These enzymes are known to metabolize the anthracyclines doxorubicin (DOX) and daunorubicin (DAUN). Both DOX and DAUN are highly effective in cancer therapy; however, there is considerable interpatient variability in adverse effects seen in patients undergoing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcohol Oxidoreductases
Share to Antibiotics, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biotransformation

Share to Chromatography, High Pressure Liquid

Share to Daunorubicin

Share to Doxorubicin

Share to Recombinant Proteins

Share to Vitamin K 3

Source

Identifiers

PMID: 19204081
DOI: 10.1124/dmd.108.024711

Genes

CBR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.PMID 19204081Read ↗

Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.Semantic proximity Read ↗

Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism.Semantic proximity Read ↗

Two allelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin.Semantic proximity Read ↗

A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity.Semantic proximity Read ↗

Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218.Semantic proximity Read ↗

Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.Semantic proximity Read ↗

Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy.Semantic proximity Read ↗

Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.Semantic proximity Read ↗

CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.Semantic proximity Read ↗

Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.Semantic proximity Read ↗

Pharmacogenetics of genes across the doxorubicin pathway.Semantic proximity Read ↗

Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.